This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
3 Mar 2011

European Commission Supports Avastin As An Effective Treatment for Breast Cancer

The European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe.

Roche announced yesterday that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe.

 

The decision follows recent recommendations made by the Committee for Medicinal Products for Human Use (CHMP) that Avastin in combination with paclitaxel has been convincingly shown to enable women with metastatic breast cancer to live longer without their disease getting worse (progression-free survival) and that the combination is a valuable treatment option.

 

Paclitaxel is the chemotherapy most frequently used in Europe and also most frequently partnered with Avastin for the first-

Related News